Reprogramming mRNA With CRISPR Could End Prostate Cancer's Immunotherapy Resistance
Researchers have pioneered a CRISPR-based method to lengthen shortened mRNA in prostate tumors, making them visible to the immune system. This breakthrough transforms 'immune cold' tumors into targets that respond effectively to existing checkpoint therapies.
Prostate cancer has long remained shielded from the body's natural defenses, earning a reputation among oncologists as an immune cold tumor. These malignancies fail to attract T cells, rendering modern immunotherapy largely ineffective. However, a collaborative research effort led by the Duke University School of Medicine and the University of Rochester Medicine suggests that a precision CRISPR intervention could dismantle this biological defense mechanism.
The Mechanism of Tumor Invisibility
The resistance stems from a cellular adaptation discovered by Dr. Eric J. Wagner and his colleagues over a decade ago. In various cancers, messenger RNA (mRNA) molecules physically shorten their structures. These truncated molecules are more stable and resistant to enzymatic degradation, allowing them to produce excessive amounts of specific proteins without normal cellular regulation. In prostate cancer, this process targets the SPSB1 protein.
The research, published in Nature Biomedical Engineering, outlines a specific chain of events that hides the tumor:
- Shortened mRNA leads to an overproduction of the SPSB1 protein.
- SPSB1 actively destroys the MHC-1 complex, a molecular signal that identifies cancer cells to T cells.
- The loss of MHC-1 removes the magnet required to draw immune cells into the tumor environment.
CRISPR Cas13 as a Molecular Anchor
To reverse this, the team engineered a unique CRISPR Cas13 system. Unlike traditional gene-editing tools that function by cutting genetic material, this experimental RNA-targeting technology acts as a physical block. By binding to a specific section of the mRNA, the tool prevents the cancer cell from shortening the molecule's tail. Maintaining the mRNA at its natural length successfully restricts SPSB1 production, which in turn allows the MHC-1 complex to reappear on the cell surface.
Laboratorial trials using mouse models demonstrated that once these signals were restored, immune checkpoint therapies—which previously failed—could successfully launch an attack. The study further noted that the treatment produced no detectable off-target effects, suggesting a high degree of precision.
Expanding Beyond Prostate Cancers
Dr. Wagner emphasizes that immunotherapy offers a superior alternative to traditional drugs because it avoids damaging healthy cells. He notes that while cancer is adept at evolution, it cannot easily overcome a synergistic approach that combines immunotherapy with tools that artificially amplify the immune response. Looking forward, the researchers are applying this technology to other resistant malignancies, including pancreatic cancer, with ongoing support from the National Cancer Institute and the Wilmot Cancer Institute.
Source: ScienceDaily
